Belite Bio (BLTE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.70
- EPS estimate
- −$0.78
- EPS surprise
- +9.89%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 13, 2026
Belite Bio reported Q2 2026 results on August 13, 2026. It posted a loss of $0.70 per share, narrower than the expected $0.78 loss, which the source counts as a 9.89% beat. The table shows no revenue figures or revenue estimates for any quarter. Compared with Q2 2025, the loss per share widened by 40% from $0.50.
Every quarter in the table is a loss, and the losses have widened recently. Full-year losses were $1.24 per share in 2023 and $1.18 in 2024, then widened by about 68% to $1.98 in 2025. The first half of 2026 lost $1.04 per share, about 9.5% more than the $0.95 lost a year earlier. Q2 2026 was the largest quarterly loss in the table, while Q4 2023 was the smallest, at $0.25. Results against estimates have been evenly split: seven quarters came in better than expected and seven worse. The last three quarters all came in better than the estimate.
Q3 results came out between November 10 and November 14 in each of the past three years. That points to mid-November 2026 for the next report, which will show whether the quarterly loss keeps widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.78 | −$0.70 | +9.89% | $0.00 | SEC |
| Q1 2026 | May 20, 2026 | −$0.63 | −$0.34 | +46.45% | $0.00 | SEC |
| Q4 2025 | Mar 2, 2026 | −$0.55 | −$0.38 | +30.44% | $0.00 | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.49 | −$0.65 | −33.33% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.41 | −$0.50 | −21.95% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.35 | −$0.45 | −27.84% | $0.00 | SEC |
| Q4 2024 | Mar 17, 2025 | −$0.31 | −$0.32 | −3.90% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.29 | −$0.28 | +2.78% | $0.00 | SEC |
| Q2 2024 | Aug 9, 2024 | −$0.26 | −$0.31 | −21.09% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.29 | −$0.27 | +5.26% | $0.00 | SEC |
| Q4 2023 | Mar 12, 2024 | −$0.30 | −$0.25 | +16.67% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.32 | −$0.40 | −25.00% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.30 | −$0.26 | +12.61% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.20 | −$0.33 | −65.00% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Belite Bio (BLTE) last report earnings?
Belite Bio last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did BLTE beat earnings estimates?
Yes. Belite Bio reported EPS of −$0.70 for Q2 2026 against a −$0.78 estimate — a 9.89% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.